Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$2.35 +4.0%	$2.80	$2.06 ▼ $40.32	$6.55M	-0.32	140,911 shs	63,104 shs
ARTL Artelo Biosciences	$9.53 -0.5%	$11.51	$4.92 ▼ $28.60	$6.75M	1.36	127,100 shs	7,413 shs
GLUC Glucose Health	$0.09 -1.1%	$0.10	$0.08 ▼ $0.28	$1.58M	1.79	6,336 shs	200 shs
GNPX GENPREX	$0.14 -11.7%	$0.25	$0.14 ▼ $3.97	$5.45M	-0.53	1.65 million shs	3.07 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	-3.42%	-6.61%	-30.67%	-36.52%	-94.28%
ARTL Artelo Biosciences	-3.23%	-5.43%	-34.16%	+67.19%	+21.88%
GLUC Glucose Health	-1.09%	-9.45%	-7.61%	-3.40%	-63.60%
GNPX GENPREX	-4.23%	-27.66%	-37.37%	-38.25%	-75.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALZN Alzamend Neuro	2.6091 of 5 stars	3.5	2.0	0.0	0.0	1.1	3.3	0.6
ARTL Artelo Biosciences	2.8754 of 5 stars	3.8	5.0	0.0	0.0	1.6	0.0	0.6
GLUC Glucose Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GNPX GENPREX	1.515 of 5 stars	0.0	3.0	0.0	4.7	2.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALZN Alzamend Neuro	3.00	Buy	$45.00	1,814.89% Upside
ARTL Artelo Biosciences	3.60	Strong Buy	$24.00	151.84% Upside
GLUC Glucose Health	0.00	N/A	N/A	N/A
GNPX GENPREX	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GLUC, GNPX, ARTL, and ALZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	ALZN Alzamend Neuro	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$180.00 ➝ $45.00
8/18/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/4/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
7/8/2025	ARTL Artelo Biosciences	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/8/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00
6/11/2025	ARTL Artelo Biosciences	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/6/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	$4.95 per share	N/A
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	($2.00) per share	N/A
GLUC Glucose Health	$380K	4.17	N/A	N/A	N/A	∞
GNPX GENPREX	N/A	N/A	N/A	N/A	$0.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALZN Alzamend Neuro	-$4.51M	N/A	0.00	N/A	N/A	N/A	-181.34%	-116.84%	9/10/2025 (Estimated)
ARTL Artelo Biosciences	-$9.83M	-$19.05	N/A	N/A	N/A	N/A	-497.68%	-213.76%	N/A
GLUC Glucose Health	-$320K	-$0.03	N/A	∞	N/A	-82.29%	N/A	N/A	N/A
GNPX GENPREX	-$21.11M	N/A	0.00	N/A	N/A	N/A	-809.27%	-386.95%	N/A

Latest GLUC, GNPX, ARTL, and ALZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2025	N/A	ALZN Alzamend Neuro	-$3.69	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	GNPX GENPREX	-$0.71	-$0.17	+$0.54	-$0.17	N/A	N/A
8/13/2025	Q2 2025	ARTL Artelo Biosciences	-$0.13	-$5.61	-$5.48	-$5.61	N/A	N/A
8/8/2025	Q2 2025	GLUC Glucose Health	N/A	-$0.01	N/A	-$0.01	N/A	$0.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	N/A
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	N/A
GLUC Glucose Health	N/A	N/A	N/A	N/A	N/A
GNPX GENPREX	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALZN Alzamend Neuro	N/A	6.58	6.58
ARTL Artelo Biosciences	N/A	0.39	0.39
GLUC Glucose Health	N/A	N/A	N/A
GNPX GENPREX	N/A	0.84	1.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALZN Alzamend Neuro	49.61%
ARTL Artelo Biosciences	0.87%
GLUC Glucose Health	N/A
GNPX GENPREX	14.05%

Insider Ownership

Company	Insider Ownership
ALZN Alzamend Neuro	30.21%
ARTL Artelo Biosciences	5.80%
GLUC Glucose Health	N/A
GNPX GENPREX	0.44%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALZN Alzamend Neuro	4	2.90 million	2.02 million	No Data
ARTL Artelo Biosciences	5	700,000	663,000	Not Optionable
GLUC Glucose Health	147,000	17.41 million	N/A	Not Optionable
GNPX GENPREX	20	33.47 million	33.32 million	No Data

GLUC, GNPX, ARTL, and ALZN Headlines

Recent News About These Companies

Genprex receives notice of allowance for multiple patents for Reqorsa

August 18 at 2:30 PM | msn.com

Genprex Secures Patent Allowances for Gene Therapy

August 18 at 9:59 AM | tipranks.com

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

August 18 at 9:29 AM | prnewswire.com

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

August 4, 2025 | prnewswire.com

Genprex, Inc. (GNPX) Latest Stock News & Headlines - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Genprex reports positive results from diabetes gene therapy study

June 25, 2025 | investing.com

Genprex Announces Positive Preclinical Results for GPX-002

June 24, 2025 | tipranks.com

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

June 24, 2025 | prnewswire.com

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

June 23, 2025 | prnewswire.com

Genprex to Participate at BIO 2025 International Convention

June 3, 2025 | prnewswire.com

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 29, 2025 | prnewswire.com

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

May 28, 2025 | prnewswire.com

Genprex and University of Pittsburgh sign new agreement to study GPX-002 for diabetes

May 9, 2025 | bioworld.comB

Genprex inks sponsored research agreement with the University of Pittsburgh to study diabetes gene therapy in Type 1 and Type 2 diabetes

May 8, 2025 | pharmabiz.comP

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

May 7, 2025 | prnewswire.com

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

May 6, 2025 | prnewswire.com

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

April 30, 2025 | prnewswire.com

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

April 29, 2025 | prnewswire.com

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

April 28, 2025 | prnewswire.com

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

April 24, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUC, GNPX, ARTL, and ALZN Company Descriptions

Alzamend Neuro NASDAQ:ALZN

$2.35 +0.09 (+3.98%)

Closing price 04:00 PM Eastern

Extended Trading

$2.36 +0.00 (+0.21%)

As of 07:31 PM Eastern

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Artelo Biosciences NASDAQ:ARTL

$9.53 -0.05 (-0.52%)

Closing price 03:59 PM Eastern

Extended Trading

$9.56 +0.03 (+0.26%)

As of 06:09 PM Eastern

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Glucose Health OTCMKTS:GLUC

$0.09 0.00 (-1.09%)

As of 02:05 PM Eastern

Glucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.

GENPREX NASDAQ:GNPX

$0.14 -0.02 (-11.72%)

Closing price 03:59 PM Eastern

Extended Trading

$0.15 +0.01 (+3.62%)

As of 07:51 PM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time